{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000128","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.709642+00:00","generated_at":"2026-05-31T05:54:22.498043+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Summit reports ivonescimab beats Keytruda in Phase 3 NSCLC trial; PFS HR=0.51 p<0.0001","bullets":["Ivonescimab vs pembrolizumab in 1L PD-L1+ advanced NSCLC: mPFS 11.14 vs 5.82 months (HR 0.51, p<0.0001).","ORR 50.0% vs 38.5%, DCR 89.9% vs 70.5%. OS not yet mature; safety manageable.","Subgroup benefit consistent: PD-L1 TPS≥50% HR 0.46; squamous HR 0.48; non-squamous HR 0.54.","Phase II perioperative AK112-205 in resectable NSCLC: MPR 71.8% (cohort 2), pCR 43.6% with ivonescimab+chemo.","Additional Phase II data in breast, colorectal, head & neck cancers released at ESMO; conference call Sep 9."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000128","json":"https://secwatch.observer/filing/0001599298-24-000128.json","markdown":"https://secwatch.observer/filing/0001599298-24-000128.md","text":"https://secwatch.observer/filing/0001599298-24-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000128/0001599298-24-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000128/smmt-20240908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:54:22.498043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}